Glutamine supplementation in neonates: is there a future?

Area of Science:

• Biochemistry
• Neonatal Nutrition
• Clinical Trials

Background:

• Glutamine (GLN) is a crucial nutrient, signaling molecule, and metabolic intermediate that is rapidly depleted during physiological stress.
• Very low-birthweight (VLBW) infants often receive subnutritional GLN due to limitations in standard parenteral nutrition and delayed enteral feeding.
• Current clinical trials show mixed efficacy results for GLN supplementation in VLBW infants, with no evidence of toxicity.

Purpose of the Study:

• To review and update the evidence regarding glutamine supplementation in preterm infants.
• To evaluate whether current evidence warrants or negates further investigation into GLN supplementation for this population.
• To argue for a reevaluation of future applications and clinical trials of GLN in premature infants.

Main Methods:

• Systematic review of existing literature on glutamine supplementation in preterm infants.
• Analysis of clinical trial data regarding GLN efficacy and safety.
• Evidence-based argument for continued or revised research approaches.

Main Results:

• Glutamine is essential but often deficient in VLBW infants.
• Existing studies on GLN supplementation in VLBW infants have yielded inconsistent results regarding efficacy.
• No toxicity has been observed with GLN supplementation in clinical trials.

Conclusions:

• Despite mixed results, glutamine supplementation in VLBW infants has not become standard practice.
• The potential benefits of GLN supplementation warrant further, carefully designed investigations.
• A thoughtful reevaluation of future research and clinical applications of GLN in premature infants is necessary.